Recursion Pharmaceuticals (NASDAQ:RXRX) Sets New 52-Week Low – What’s Next?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) hit a new 52-week low on Monday . The company traded as low as $3.80 and last traded at $3.85, with a volume of 4619593 shares traded. The stock had previously closed at $4.24.

Analysts Set New Price Targets

RXRX has been the topic of several research reports. Cowen reiterated a “hold” rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Leerink Partners decreased their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a research report on Friday, February 28th. KeyCorp reduced their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Thursday, February 6th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, Recursion Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $8.25.

Recursion Pharmaceuticals Price Performance

The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The firm has a market cap of $1.66 billion, a P/E ratio of -2.69 and a beta of 1.00. The company’s 50-day moving average is $7.22 and its two-hundred day moving average is $6.95.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business had revenue of $4.60 million during the quarter, compared to the consensus estimate of $19.04 million. During the same quarter in the previous year, the business posted ($0.42) EPS. The company’s revenue for the quarter was down 57.8% on a year-over-year basis. Sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Softbank Group CORP. bought a new position in Recursion Pharmaceuticals in the 4th quarter valued at approximately $99,152,000. Novo Holdings A S acquired a new stake in shares of Recursion Pharmaceuticals in the fourth quarter valued at about $68,375,000. Vanguard Group Inc. lifted its stake in Recursion Pharmaceuticals by 40.1% in the fourth quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company’s stock valued at $229,908,000 after buying an additional 9,737,196 shares during the period. State Street Corp increased its stake in Recursion Pharmaceuticals by 47.1% in the third quarter. State Street Corp now owns 12,870,272 shares of the company’s stock valued at $84,815,000 after purchasing an additional 4,120,685 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of Recursion Pharmaceuticals during the fourth quarter valued at about $23,429,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.